Next Article in Journal
Bioinformatics and Functional Analysis of a New Nuclear Localization Sequence of the Influenza A Virus Nucleoprotein
Previous Article in Journal
Timing of Blood Sample Processing Affects the Transcriptomic and Epigenomic Profiles in CD4+ T-cells of Atopic Subjects
 
 
Review

Neuroinflammation in Dementia—Therapeutic Directions in a COVID-19 Pandemic Setting

1
Department of Psychiatry, Wroclaw Medical University, 50-367 Wroclaw, Poland
2
Department of Pathology, Wroclaw Medical University, 50-367 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Dolores Viña
Cells 2022, 11(19), 2959; https://doi.org/10.3390/cells11192959
Received: 8 August 2022 / Revised: 16 September 2022 / Accepted: 20 September 2022 / Published: 22 September 2022
Although dementia is a heterogenous group of diseases, inflammation has been shown to play a central role in all of them and provides a common link in their pathology. This review aims to highlight the importance of immune response in the most common types of dementia. We describe molecular aspects of pro-inflammatory signaling and sources of inflammatory activation in the human organism, including a novel infectious agent, SARS-CoV-2. The role of glial cells in neuroinflammation, as well as potential therapeutic approaches, are then discussed. Peripheral immune response and increased cytokine production, including an early surge in TNF and IL-1β concentrations activate glia, leading to aggravation of neuroinflammation and dysfunction of neurons during COVID-19. Lifestyle factors, such as diet, have a large impact on future cognitive outcomes and should be included as a crucial intervention in dementia prevention. While the use of NSAIDs is not recommended due to inconclusive results on their efficacy and risk of side effects, the studies focused on the use of TNF antagonists as the more specific target in neuroinflammation are still very limited. It is still unknown, to what degree neuroinflammation resulting from COVID-19 may affect neurodegenerative process and cognitive functioning in the long term with ongoing reports of chronic post-COVID complications. View Full-Text
Keywords: neuroinflammation; TNF; SARS-CoV-2; COVID-19; glial cells; TNF antagonists neuroinflammation; TNF; SARS-CoV-2; COVID-19; glial cells; TNF antagonists
Show Figures

Figure 1

MDPI and ACS Style

Łuc, M.; Woźniak, M.; Rymaszewska, J. Neuroinflammation in Dementia—Therapeutic Directions in a COVID-19 Pandemic Setting. Cells 2022, 11, 2959. https://doi.org/10.3390/cells11192959

AMA Style

Łuc M, Woźniak M, Rymaszewska J. Neuroinflammation in Dementia—Therapeutic Directions in a COVID-19 Pandemic Setting. Cells. 2022; 11(19):2959. https://doi.org/10.3390/cells11192959

Chicago/Turabian Style

Łuc, Mateusz, Marta Woźniak, and Joanna Rymaszewska. 2022. "Neuroinflammation in Dementia—Therapeutic Directions in a COVID-19 Pandemic Setting" Cells 11, no. 19: 2959. https://doi.org/10.3390/cells11192959

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop